Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962723 | 0.91 | PPARG (0.49) | EPHX2KDM4EPPARG | |
| SCHEMBL1964681 | 0.87 | PPARG (0.47) | EPHX2KDM4ETP53TSHRPPARG | |
| SCHEMBL1964650 | 0.86 | ALDH1A1 (0.48) | KDM4ETP53TSHRPPARG | |
| SCHEMBL1963157 | 0.86 | EPHX2 (0.52) | EPHX2KDM4ETP53TSHRSYK | |
| SCHEMBL1961347 | 0.79 | AKR1C3 (0.57) | TP53TSHR | |
| SCHEMBL1962517 | 0.78 | KMT2A (0.46) | KDM4ETSHR | |
| SCHEMBL1961839 | 0.78 | KMT2A (0.48) | KDM4ETSHRKCNH2 | |
| SCHEMBL1962720 | 0.77 | EGFR (0.51) | EPHX2KDM4EPPARG | |
| SCHEMBL1417060 | 0.77 | L3MBTL1 (0.66) | KDM4ETP53TSHRPPARG | |
| SCHEMBL15163136 | 0.76 | MAPK14 (0.50) | EPHX2KDM4ETP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8481568-B2 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| EP-1919892-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SI, CYP3A5, CYP2D6 | EPHX2 696/4885KDM4E 1501/4885TP53 245/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | EPHX2 696/4885KDM4E 1501/4885TP53 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.